Launch Decisions of Pharmaceutical Companies

Journal Title: Journal of Economics and Financial Analysis - Year 2017, Vol 1, Issue 1

Abstract

This paper models the launch decision of pharmaceutical companies in regard to new drugs and country markets. New drugs are launched with a delay or not launched at all in many countries. Considering that many of these new drugs would have created health benefits to the patients, there seems to be welfare loss. We use market characteristics to explain this phenomenon. We show that most of the estimated launch with a delay and no-launch decision is due to observable market characteristics. The model has an accuracy of 70 percent in explaining the no-launch decision. Intellectual property rights protection is especially important. The policy implication is that stronger property rights increase the likelihood and speed of new drug launch.

Authors and Affiliations

Abdulkadir Civan, Michael Maloney

Keywords

Related Articles

Nonprofit Organizations in Disaster Response and Management: A Network Analysis

This paper tracks changes in the national disaster management system with regard to the nonprofit sector by looking at the roles ascribed to nonprofit organizations in the Federal Response Plan (FRP), National Response P...

Analysis of Equity β Components: New Results and Prospectives in a Low β Framework

This work aims to exploit the so-called "Beta anomaly" regarding the risk-reward relationship, and set up rules and methodologies in order to build new efficient portfolios. It is well known in literature, and among prac...

Measuring Predictability of Oil and Gas Stock Returns and Performance of Moving Average Trading Rules

The paper re-examines whether investors can predict oil and gas stock prices for abnormal returns using autocorrelation-based trading and filter rules and moving average strategies. In this paper, short and long lengths...

Financial Contagion in the BRICS Stock Markets: An empirical analysis of the Lehman Brothers Collapse and European Sovereign Debt Crisis

This research analyzes and extends the study of contagion for BRICS emerging stock markets in the context of the last two international financial crises: the Lehman Brothers Bankruptcy Crisis and the European Sovereign D...

The causality between Financial Development and Economic Growth in Ethiopia: Supply Leading vs Demand Following Hypothesis

This paper investigates linkage between financial development and economic growth in Ethiopia during the period from 1975 to 2016 using Autoregressive Distributed Lag (ARDL) approach. The paper also schedules Vector Erro...

Download PDF file
  • EP ID EP246290
  • DOI -
  • Views 123
  • Downloads 0

How To Cite

Abdulkadir Civan, Michael Maloney (2017). Launch Decisions of Pharmaceutical Companies. Journal of Economics and Financial Analysis, 1(1), 35-58. https://europub.co.uk./articles/-A-246290